Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yijia Hua

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Bosnian Journal of Basic Medical Sciences|November 11, 2021
The prognostic value of MKL1 in predicting breast cancer immune infiltrates and chemosensitivityYijia Hua, Mengzhu Yang
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|November 13, 2024
Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussionXiang Huang, Yijia Hua, Chunxiao Sun, et al.
Frontiers in Oncology|May 16, 2022
Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case ReportNan Jin, Chunxiao Sun, Yijia Hua, et al.
Cancers|March 28, 2024
An Imbalance in Histone Modifiers Induces tRNA-Cys-GCA Overexpression and tRF-27 Accumulation by Attenuating Promoter H3K27me3 in Primary Trastuzumab-Resistant Breast CancerNingjun Duan, Yijia Hua, Xueqi Yan, et al.
Biomarker Research|May 30, 2024
The war between the immune system and the tumor - using immune biomarkers as tracersKai Yang, Rongrong Lu, Jie Mei, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 9, 2024
Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast CancerNingjun Duan, Yijia Hua, Xueqi Yan, et al.
Therapeutic Advances in Medical Oncology|March 31, 2022
Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world studyYijia Hua, Wei Li, Nan Jin, et al.
International Journal of Cancer|August 11, 2025
An open-label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2-negative metastatic breast cancerXinyu Wu, Fei Qu, Yijia Hua, et al.
Analytical Chemistry|December 12, 2025
Integrated Biomimetic Platform for Enhancing the Efficient Capture and Visual Identification of Circulating Tumor CellsTianyu Zeng, Ben Li, Jialin Xu, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|August 30, 2025
m6A mRNA methylation initiated by METTL14 promotes STK11 translation and increases STK11 activity to induce anti-HER2 therapy resistance in breast cancerFan Yang, Pei Ma, Yaozhou He, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Bosnian Journal of Basic Medical Sciences|November 11, 2021
The prognostic value of MKL1 in predicting breast cancer immune infiltrates and chemosensitivityYijia Hua, Mengzhu Yang
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|November 13, 2024
Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussionXiang Huang, Yijia Hua, Chunxiao Sun, et al.
Frontiers in Oncology|May 16, 2022
Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case ReportNan Jin, Chunxiao Sun, Yijia Hua, et al.
Cancers|March 28, 2024
An Imbalance in Histone Modifiers Induces tRNA-Cys-GCA Overexpression and tRF-27 Accumulation by Attenuating Promoter H3K27me3 in Primary Trastuzumab-Resistant Breast CancerNingjun Duan, Yijia Hua, Xueqi Yan, et al.
Biomarker Research|May 30, 2024
The war between the immune system and the tumor - using immune biomarkers as tracersKai Yang, Rongrong Lu, Jie Mei, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 9, 2024
Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast CancerNingjun Duan, Yijia Hua, Xueqi Yan, et al.
Therapeutic Advances in Medical Oncology|March 31, 2022
Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world studyYijia Hua, Wei Li, Nan Jin, et al.
International Journal of Cancer|August 11, 2025
An open-label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2-negative metastatic breast cancerXinyu Wu, Fei Qu, Yijia Hua, et al.
Analytical Chemistry|December 12, 2025
Integrated Biomimetic Platform for Enhancing the Efficient Capture and Visual Identification of Circulating Tumor CellsTianyu Zeng, Ben Li, Jialin Xu, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|August 30, 2025
m6A mRNA methylation initiated by METTL14 promotes STK11 translation and increases STK11 activity to induce anti-HER2 therapy resistance in breast cancerFan Yang, Pei Ma, Yaozhou He, et al.
Pageof 2